Raymond James Downgrades AMAG Pharmaceuticals (AMAG) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
AMAG Pharmaceuticals Provides Financial and Business Update
January 9, 2017 8:01 AM EST2016 total revenue increased 45 percent
Provides update on Makena® next-generation program
Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million
WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided a business update, including announcing preliminary unaudited fourth quarter and annual 2016 financial results, 2017 financial guidance, and an update on its Makena® subcutaneous auto-injector program. In a separate release, the company also announced a licensing transaction for RekyndaTM (bremelanotide). The company will present further... More
AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
January 9, 2017 8:00 AM ESTTwo Phase 3 trials completed for Rekynda; co-primary endpoints met
Will address underserved medical condition with significant untapped market potential
Broadens AMAGs presence in womens health and leverages AMAGs commercial capabilities and customer relationships
WALTHAM, Mass. and CRANBURY, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) together with Palatin Technologies, Inc. (NYSE MKT: PTN) today announced they have entered into an agreement for exclusive North American rights to develop... More
